Marinus Pharmaceuticals Company Insiders

Marinus Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.5775) % which means that it has lost $0.5775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.8655) %, meaning that it created substantial loss on money invested by shareholders. Marinus Pharmaceuticals' management efficiency ratios could be used to measure how well Marinus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.87 in 2024. Return On Capital Employed is likely to drop to -1.06 in 2024. At this time, Marinus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 9.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 778 K in 2024. Common Stock Shares Outstanding is likely to gain to about 56.4 M in 2024, whereas Net Loss is likely to drop (18.7 M) in 2024.

Marinus Pharmaceuticals Workforce Comparison

Marinus Pharmaceuticals Insider Trading

Marinus Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Marinus Pharmaceuticals often depends on how effective the management is. Marinus Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Marinus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Marinus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Marinus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Marinus Pharmaceuticals. Check Marinus Pharmaceuticals' Beneish M Score to see the likelihood of Marinus Pharmaceuticals' management manipulating its earnings.

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.